Clinical trial for NSCLC
Official title Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT06865339
What this study is testing
What is Cemiplimab?
An investigational once‑weekly injectable medicine being studied for locally advanced non‑small cell lung cancer (LA‑NSCLC). It is designed to block the PD‑1 protein on immune cells, helping the immune system recognize and attack cancer cells.
Also referred to as REGN2810 (PD1)_cemiplimab_LIBTAYO.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how well the drugs shrink tumors by measuring response rates on PET scans after three treatment cycles.
- Who it's for
- Adults who have locally advanced non‑small cell lung cancer and are eligible for immunotherapy.
- What's involved
- Participants receive three cycles of the two immune drugs, no chemotherapy, and undergo PET scans to check tumor response.
- Time commitment
- The study lasts about three months, with regular visits for drug administration and PET scans.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Previously untreated and biopsy-proven NSCLC, with measurable disease (at least 1 unidimensional, radiographically measurable lesion based on RECIST...
- AJCC version 8 Stage II disease, medically or technically unresectable
- AJCC version 8 Stage III disease, eligible for non-surgical treatment
- Determination of PD-L1 expression on pretreatment tumor specimen using a clinically validated assay
- Eligible for standard nonsurgical treatment for Stage III NSCLC, i.e., chemotherapy and concurrent RT followed by adjuvant durvalumab
You likely can't join if
- Not a woman of childbearing potential (WOCBP) as defined in the Appendix
- A WOCBP who agrees to follow the contraceptive guidance in the Appendix during the treatment period and for at least 6 months (180 days) after the...
- A WOCBP who agrees to follow the contraceptive guidance in the Appendix and for at least 6 months after the last dose of chemotherapy or as specified...
- A male participant must agree to use contraception during the treatment period and for at least 6 months after the last dose of study treatment and...
- Presence of known sensitizing epidermal growth factor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion o Determination of EGFR/ALK mutation...
- Prior therapy with an anti-PD-1, anti-PD-L1, or LAG-3 inhibitor
See the full eligibility criteria
Who can join
- Previously untreated and biopsy-proven NSCLC, with measurable disease (at least 1 unidimensional, radiographically measurable lesion based on RECIST v1.1) and one of the following stages: (prior resection or...
- AJCC version 8 Stage II disease, medically or technically unresectable
- AJCC version 8 Stage III disease, eligible for non-surgical treatment
- Determination of PD-L1 expression on pretreatment tumor specimen using a clinically validated assay
- Eligible for standard nonsurgical treatment for Stage III NSCLC, i.e., chemotherapy and concurrent RT followed by adjuvant durvalumab
- Whole body PET/CT within 42 days prior to study entry demonstrating hypermetabolic pulmonary lesion(s) and/or thoracic lymph node(s)
- MRI of the brain or head CT with contrast within 42 days prior to study entry
- PFTs within 42 days of study entry
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Hemoglobin ≥ 9.0 g/dL
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (\> 1500 per mm3)
- Platelet count ≥ 100 x 109/L (\>100,000 per mm3)
- Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). This will not apply to people with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the...
- AST (SGOT)/ALT (SGPT), and alkaline phosphatase ≤ 2.5 x institutional upper limit of normal (ULN)
- Serum creatinine clearance \>30 mL/min by the Cockcroft-Gault formula (as below) or by 24-hour urine collection for determination of creatinine clearance: (except for patients planned to receive pemetrexed, in which...
- Males: Weight (kg) x (140 - Age) ÷ (72 x serum creatinine (mg/dL))
- Females: 0.85 x Weight (kg) x (140 - Age) ÷ (72 x serum creatinine (mg/dL))
- A female participant is eligible to participate if she is not pregnant (see
What rules you out
- Not a woman of childbearing potential (WOCBP) as defined in the Appendix
- A WOCBP who agrees to follow the contraceptive guidance in the Appendix during the treatment period and for at least 6 months (180 days) after the last dose of study treatment with cemiplimab and fianlimab
- A WOCBP who agrees to follow the contraceptive guidance in the Appendix and for at least 6 months after the last dose of chemotherapy or as specified in FDA prescribing labels (e.g.
- A male participant must agree to use contraception during the treatment period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period
- Presence of known sensitizing epidermal growth factor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion o Determination of EGFR/ALK mutation status is required for non-squamous cell carcinoma histologies and...
- Prior therapy with an anti-PD-1, anti-PD-L1, or LAG-3 inhibitor
- Patient currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
- Active malignancy other than lung cancer that (1) requires active treatment other than hormonal therapy and (2) is deemed by the treating physicians to be likely to affect the patient's life expectancy
- A history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- Known history of myocarditis
- Troponin T (TnT) or troponin I (TnI) \> 2x institutional ULN at baseline. Patients with TnT or TnI levels between \> 1 to 2x ULN are permitted if repeat levels within 24 hours are ≤ 1x ULN.
- Known active Bacillus Tuberculosis (TB)
- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Pregnancy, assessed with urine pregnancy test within 72 hours prior to study treatment allocation. If urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents.
- History or current evidence of significant (CTCAE grade ≥2) local or systemic infection (e.g., cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial...
- Active infection requiring therapy
- Uncontrolled infection with HIV, Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection
- Patients with known HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are permitted.
- Patients with known hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted.
- Patients who are known hepatitis C virus antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by polymerase chain reaction (PCR) either spontaneously or in response to a successful prior...
- Patients with HIV or hepatitis must be reviewed by a qualified specialist (e.g., infectious disease or hepatologist) managing this disease prior to commencing and regularly throughout the duration of their participation...
- Diagnosis of immunodeficiency or ongoing chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose...
- Known hypersensitivity to the active substances or to any of the excipients
- Received a live vaccine within 30 days of planned start of study medication o Live or live attenuated vaccination with replicating potential.
The study team makes the final eligibility decision.
Where it is enrolling
- The Bronx, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at The Bronx, New York, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.